Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

R. Giusti · SciRah

Researcher profile · Semantic Scholar

R. Giusti

Share profile

R. Giusti — researcher profile on SciRah

h-index: 34
Works: 145
Citations: 5,500

Most-cited papers

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
M. Garassino, J. Whisenant, Li-Ching Huang, A. Trama +45 more
2020The Lancet Oncology498 citations Open access
Semantic Scholar
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
A. Cortellini, M. Tucci, V. Adamo, L. S. Stucci +36 more
2020Journal for ImmunoTherapy of Cancer239 citations Open access
Semantic Scholar
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.
D. Marinelli, M. Mazzotta, S. Scalera, I. Terrenato +26 more
2020Annals of Oncology199 citations Open access
Semantic Scholar
Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment
A. Botticelli, P. Vernocchi, F. Marini, Andrea Quagliariello +12 more
2020Journal of Translational Medicine189 citations Open access
Semantic Scholar
Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists’ perspective
M. Lambertini, A. Toss, A. Passaro, C. Criscitiello +9 more
2020ESMO Open179 citations Open access
Semantic Scholar
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
A. Cortellini, M. di Maio, O. Nigro, A. Leonetti +57 more
2021Journal for ImmunoTherapy of Cancer151 citations Open access
Semantic Scholar
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study.
C. Nebhan, A. Cortellini, Wei-Jie Ma, Teja Ganta +41 more
2021JAMA Oncology144 citations Open access
Semantic Scholar
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
A. Cortellini, M. Bersanelli, D. Santini, S. Buti +34 more
2020European Journal of Cancer112 citations
Semantic Scholar
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
S. Buti, M. Bersanelli, F. Perrone, M. Tiseo +43 more
2020European Journal of Cancer103 citations Open access
Semantic Scholar
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study
D. Pinato, J. Tabernero, M. Bower, L. Scotti +116 more
2021The Lancet Oncology95 citations Open access
Semantic Scholar
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
A. Cortellini, M. Tiseo, G. Banna, F. Cappuzzo +66 more
2020Cancer Immunology and Immunotherapy94 citations Open access
Semantic Scholar
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
A. Cortellini, B. Ricciuti, M. Tiseo, E. Bria +46 more
2020Journal for ImmunoTherapy of Cancer92 citations Open access
Semantic Scholar
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes.
A. Cortellini, A. Friedlaender, G. Banna, G. Porzio +67 more
2020Clinical Lung Cancer79 citations Open access
Semantic Scholar
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study
D. Pinato, J. Aguilar-Company, D. Ferrante, G. Hanbury +143 more
2022The Lancet Oncology73 citations Open access
Semantic Scholar
Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up.
P. Roth, A. Pace, E. Le Rhun, M. Weller +13 more
2020Annals of Oncology73 citations Open access
Semantic Scholar
Next-Generation Sequencing in Clinical Practice: Is It a Cost-Saving Alternative to a Single-Gene Testing Approach?
G. Pruneri, F. De Braud, A. Sapino, M. Aglietta +9 more
2021PharmacoEconomics - Open71 citations Open access
Semantic Scholar
Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer.
A. Cortellini, A. D'Alessio, S. Cleary, S. Buti +54 more
2023Clinical Cancer Research70 citations Open access
Semantic Scholar
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: a multicentre study.
O. Nigro, G. Pinotti, F. de Galitiis, F. Di Pietro +47 more
2020medRxiv65 citations Open access
Semantic Scholar
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.
C. Celsa, G. Cabibbo, Claudia Am Fulgenzi, B. Scheiner +68 more
2023Journal of Hepatology63 citations Open access
Semantic Scholar
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer
G. Banna, A. Cortellini, D. Cortinovis, M. Tiseo +42 more
2021ESMO Open61 citations Open access
Semantic Scholar
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario
L. Cantini, G. Mentrasti, G. L. Russo, D. Signorelli +58 more
2022ESMO Open60 citations Open access
Semantic Scholar
The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy
A. Botticelli, A. Cirillo, S. Scagnoli, B. Cerbelli +17 more
2020Vaccines60 citations Open access
Semantic Scholar
KEAP1 and TP53 frame genomic, evolutionary and immunological subtypes of lung adenocarcinoma with different sensitivity to immunotherapy.
S. Scalera, M. Mazzotta, G. Corleone, F. Sperati +21 more
2021Journal of Thoracic Oncology56 citations Open access
Semantic Scholar
A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab
A. Botticelli, M. Salati, F. Di Pietro, L. Strigari +10 more
2019Journal of Translational Medicine54 citations Open access
Semantic Scholar
Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1
A. Botticelli, S. Mezi, G. Pomati, B. Cerbelli +10 more
2020Frontiers in Immunology49 citations Open access
Semantic Scholar
Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study
A. Cortellini, A. De Giglio, K. Cannita, D. Cortinovis +47 more
2021Thoracic Cancer48 citations Open access
Semantic Scholar
Management of Opioid-Induced Constipation and Bowel Dysfunction: Expert Opinion of an Italian Multidisciplinary Panel
R. De Giorgio, F. Zucco, G. Chiarioni, S. Mercadante +6 more
2021Advances in Therapy46 citations Open access
Semantic Scholar
Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis.
M. Filetti, P. Lombardi, R. Giusti, R. Falcone +6 more
2023Cancer Treatment Reviews34 citations Open access
Semantic Scholar
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
A. Cortellini, K. Cannita, M. Tiseo, D. Cortinovis +48 more
2021European Journal of Cancer31 citations Open access
Semantic Scholar
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
S. Buti, M. Bersanelli, F. Perrone, S. Bracarda +57 more
2021European Journal of Cancer31 citations Open access
Semantic Scholar
Statins and immunotherapy: Togetherness makes strength The potential effect of statins on immunotherapy for NSCLC
A. Rossi, M. Filetti, Beatrice Taurelli Salimbeni, Marta Piras +3 more
2020Cancer Reports31 citations Open access
Semantic Scholar
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry
A. Cortellini, J. Tabernero, U. Mukherjee, R. Salazar +123 more
2023The Lancet Oncology29 citations Open access
Semantic Scholar
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis
Shobana Anpalakhan, A. Signori, A. Cortellini, E. Verzoni +43 more
2023iScience28 citations Open access
Semantic Scholar
Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry.
D. Pinato, M. Patel, L. Scotti, E. Colomba +76 more
2021JAMA Oncology28 citations Open access
Semantic Scholar
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases
M. Laganà, C. Gurizzan, E. Roca, D. Cortinovis +20 more
2020Frontiers in Oncology27 citations Open access
Semantic Scholar
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study.
M. Bersanelli, S. Buti, D. Giannarelli, A. Leonetti +48 more
2020Lung Cancer26 citations Open access
Semantic Scholar
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes
A. Cortellini, A. Leonetti, A. Catino, P. Pizzutillo +33 more
2019Clinical and Translational Oncology25 citations Open access
Semantic Scholar
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG
M. Bersanelli, D. Giannarelli, U. de Giorgi, S. Pignata +69 more
2020Therapeutic Advances in Medical Oncology24 citations Open access
Semantic Scholar
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)
M. Bersanelli, D. Giannarelli, U. de Giorgi, S. Pignata +42 more
2021Journal for ImmunoTherapy of Cancer23 citations Open access
Semantic Scholar
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation
M. Russano, A. Cortellini, R. Giusti, A. Russo +46 more
2021Cancer Immunology and Immunotherapy21 citations Open access
Semantic Scholar
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry
A. Cortellini, A. Gennari, F. Pommeret, G. Patel +98 more
2022Journal of the National Cancer Institute20 citations Open access
Semantic Scholar
Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes
M. Mazzotta, M. Filetti, M. Occhipinti, D. Marinelli +24 more
2020Journal for ImmunoTherapy of Cancer20 citations Open access
Semantic Scholar
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study
M. Bersanelli, E. Verzoni, A. Cortellini, R. Giusti +64 more
2023EClinicalMedicine19 citations Open access
Semantic Scholar
Host immune‐inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD‐L1 ≥50% metastatic non‐small cell lung cancer and poor performance status receiving first‐line immunotherapy
G. Banna, M. Tiseo, D. Cortinovis, F. Facchinetti +30 more
2021Thoracic Cancer17 citations Open access
Semantic Scholar
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort
D. Santini, T. Zeppola, M. Russano, F. Citarella +44 more
2021Journal of Translational Medicine15 citations Open access
Semantic Scholar
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival
Khalil Choucair, C. Nebhan, A. Cortellini, Stijn Hentzen +22 more
2023Cancers14 citations Open access
Semantic Scholar
Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives.
D. Marinelli, R. Giusti, M. Mazzotta, M. Filetti +9 more
2020Critical reviews in oncology/hematology13 citations
Semantic Scholar
Multidisciplinary approach, continuous care and opioid management in cancer pain: case series and review of the literature
G. Porzio, A. Capela, R. Giusti, F. Lo Bianco +3 more
2023Drugs in Context12 citations Open access
Semantic Scholar
Management of orphan symptoms: ESMO Clinical Practice Guidelines for diagnosis and treatment†
D. Santini, G. Armento, R. Giusti, M. Ferrara +5 more
2020ESMO Open12 citations Open access
Semantic Scholar
Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).
A. Passaro, G. Russo, F. Passiglia, M. D'Arcangelo +20 more
2022Lung Cancer11 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Cortellini×33
Invite
A. Cortellini — researcher profile on SciRah
M. Filetti×31
Invite
M. Filetti — researcher profile on SciRah
C. Ficorella×23
Invite
C. Ficorella — researcher profile on SciRah
F. Zoratto×19
Invite
F. Zoratto — researcher profile on SciRah

×19

Invite

G. Porzio — researcher profile on SciRah

P. Marchetti×18

Invite

P. Marchetti — researcher profile on SciRah

A. Gelibter×18

Invite

A. Gelibter — researcher profile on SciRah

Invite

R. Chiari — researcher profile on SciRah

Invite

F. Mazzoni — researcher profile on SciRah

Invite

R. Berardi — researcher profile on SciRah

Invite

S. Buti — researcher profile on SciRah

Invite

F. Grossi — researcher profile on SciRah